ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

153 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Phase 3Muscular Atrophy, Spinal

Salanersen

Biogen30 participants14 sites · United States, Australia, BrazilCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

Phase 1Phase 2HIV Associated Neurocognitive DisorderHIV DementiaHIV Encephalitis

SV2A PETTSPO PET

Yale University70 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Phase 2Parkinson DiseaseParkinsonIdiopathic Parkinson Disease

NEU-411Placebo

Neuron23 Inc.150 participants72 sites · United States, Israel, ItalyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Phase 3Acute Ischemic StrokeCerebral Stroke

Drug: Normal SalineSovateltide

Pharmazz, Inc.514 participants54 sites · United States, Germany, SpainCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants17 sites · United States, South KoreaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Phase 3Stroke, Acute IschemicEndovascular ThrombectomyAcute Ischemic Stroke AIS

Tenecteplase or Alteplase- depending upon availability at each treating centreControl

University of Calgary1,500 participants13 sites · Australia, CanadaCompletes Dec 2030

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase 1Phase 2Spasticity

CorabotasePlaceboDysport

Ipsen240 participants81 sites · United States, Austria, BulgariaCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Phase 3Parkinsons Disease (PD)

bemdaneprocelSham surgery

BlueRock Therapeutics102 participants43 sites · United States, Australia, CanadaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Phase 2Intracerebral Haemorrhage

Standard treatment+mirabegronStandard treatment

Tianjin Medical University General Hospital25 participants1 site · ChinaCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

Phase 2Acute Ischemic Stroke

Anisodine HydrobromideAnisodine Hydrobromide Placebo

Capital Medical University204 participants13 sites · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Phase 3Migraine

RimegepantPlacebo

Pfizer640 participants93 sites · United States, Canada, FranceCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Phase 3Alzheimer's Disease

KarXTKarX-ECPlacebo

Bristol-Myers Squibb586 participants128 sites · United States, Argentina, AustraliaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Allopregnanolone (Zuranolone) in Post-stroke Depression

Phase 2Post Stroke Depression

Zuranolone

Duke University6 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

Phase 2Phase 3Juvenile Myoclonic Epilepsy

JZP926 capsulePlacebo

Jazz Pharmaceuticals260 participants20 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

1–15 of 153

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

153 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Phase 3Muscular Atrophy, Spinal

Salanersen

Biogen30 participants14 sites · United States, Australia, BrazilCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

Phase 1Phase 2HIV Associated Neurocognitive DisorderHIV DementiaHIV Encephalitis

SV2A PETTSPO PET

Yale University70 participants1 site · United StatesCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Phase 2Parkinson DiseaseParkinsonIdiopathic Parkinson Disease

NEU-411Placebo

Neuron23 Inc.150 participants72 sites · United States, Israel, ItalyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Phase 3Acute Ischemic StrokeCerebral Stroke

Drug: Normal SalineSovateltide

Pharmazz, Inc.514 participants54 sites · United States, Germany, SpainCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants17 sites · United States, South KoreaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Phase 3Stroke, Acute IschemicEndovascular ThrombectomyAcute Ischemic Stroke AIS

Tenecteplase or Alteplase- depending upon availability at each treating centreControl

University of Calgary1,500 participants13 sites · Australia, CanadaCompletes Dec 2030

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase 1Phase 2Spasticity

CorabotasePlaceboDysport

Ipsen240 participants81 sites · United States, Austria, BulgariaCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Phase 3Parkinsons Disease (PD)

bemdaneprocelSham surgery

BlueRock Therapeutics102 participants43 sites · United States, Australia, CanadaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Phase 2Intracerebral Haemorrhage

Standard treatment+mirabegronStandard treatment

Tianjin Medical University General Hospital25 participants1 site · ChinaCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

Phase 2Acute Ischemic Stroke

Anisodine HydrobromideAnisodine Hydrobromide Placebo

Capital Medical University204 participants13 sites · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Phase 3Migraine

RimegepantPlacebo

Pfizer640 participants93 sites · United States, Canada, FranceCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Phase 3Alzheimer's Disease

KarXTKarX-ECPlacebo

Bristol-Myers Squibb586 participants128 sites · United States, Argentina, AustraliaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

Allopregnanolone (Zuranolone) in Post-stroke Depression

Phase 2Post Stroke Depression

Zuranolone

Duke University6 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

Phase 2Phase 3Juvenile Myoclonic Epilepsy

JZP926 capsulePlacebo

Jazz Pharmaceuticals260 participants20 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

1–15 of 153